Slee T M, Vleming L J, Valentijn R M
Department of Internal Medicine, Leiden University Medical Centre, Leiden, the Netherlands.
Neth J Med. 2008 Nov;66(10):438-41.
Case report of a 62-year-old woman who developed acute renal failure due to nephrocalcinosis, also called acute phosphate nephropathy, after large bowel cleansing in preparation for colonoscopy using oral sodium phosphate solution (Phosphoral, de Witt, Cheshire, UK). Subsequently her renal insufficiency resolved only partially resulting in stage 4 chronic kidney disease. In retrospect multiple risk factors for this condition (hypertension, diuretics, AT-II receptor blocker, female gender, advanced age and volume depleting due to vomiting and nausea) were identified. If these factors had been taken into consideration prior to prescribing this drug, acute and chronic renal failure would have been prevented. Future investigation of potential risk factors and the exact mechanism of this complication is necessary to identify those patients prone to develop this complication. In the meantime prescribing physicians should be made aware of this complication. On the basis of the current state of knowledge the evidence seems to be quite compelling not to prescribe these drugs in patients with one or more associated risk factors. It could even be argued that these drugs should not be prescribed at all.
一名62岁女性的病例报告。该患者在使用口服磷酸钠溶液(Phosphoral,英国柴郡德维特公司生产)进行肠道准备以接受结肠镜检查后,因肾钙质沉着症(也称为急性磷酸盐肾病)发展为急性肾衰竭。随后,她的肾功能不全仅部分缓解,导致4期慢性肾脏病。回顾发现,该病症存在多种风险因素(高血压、利尿剂、血管紧张素II受体阻滞剂、女性、高龄以及因呕吐和恶心导致的血容量减少)。如果在开此药之前考虑到这些因素,急性和慢性肾衰竭本可避免。未来有必要对潜在风险因素及该并发症的确切机制进行研究,以识别那些容易发生此并发症的患者。与此同时,开处方的医生应了解这一并发症。基于目前的知识水平,有充分证据表明,对于有一个或多个相关风险因素的患者,不应开具这些药物。甚至可以说根本不应开具这些药物。